Alimera Sciences, Inc. (ALIM) CEO Richard Eiswirth on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 10/28/21
Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate UpdateGlobeNewsWire • 10/21/21
Analysts Estimate Alimera Sciences (ALIM) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/20/21
Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular EdemaGlobeNewsWire • 10/13/21
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual ConferenceGlobeNewsWire • 09/02/21
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in BelgiumGlobeNewsWire • 08/24/21
Alimera Sciences' (ALIM) CEO Rick Eiswirth on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/14/21
Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate UpdateGlobeNewsWire • 08/10/21
Alimera Sciences (ALIM) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 07/28/21
Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021GlobeNewsWire • 05/27/21
Alimera Sciences Inc. (ALIM) CEO Rick Eiswirth on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/01/21
Alimera Science's Innovative Treatment for Diabetic Macular Edema Vision Loss Lasts for up to 3 YearsBenzinga • 04/26/21
Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 VaccinesSeeking Alpha • 04/18/21
Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021GlobeNewsWire • 04/09/21
Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewsWire • 03/02/21